Business
Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering
About this update from Allogene Therapeutics, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, has appointed Geoffrey Parker as Executive Vice President, Chief Financial Officer. Mr. Parker will oversee the Company’s financial operations and business strategy and will serve as a member of the Leadership Team. “Geoff’s extensive experience in biotechnology across all aspects of finance and business development strategy will be of tremendous value to Allogene as we advance our critical pipeline assets and explore new opportunities,” said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. “Geoff’s commitment to excellence aligns perfectly with Allogene’s vision for the future, and I am confident he’ll be instrumental as we advance one of the most important modalities in cancer treatment.” Mr. Parker is a seasoned biotech and banking executive with nearly 40 years of leadership experience managing world-class finance and business development organizations. He has directed and managed a broad range of strategic business and finance initiatives, including equity and debt financing, initial public offerings, and business development transactions. “I am excited to join Allogene during this pivotal time in the company’s evolution,” said Mr. Parker. “My focus will be on continuing its legacy of operational excellence through the lens of financial stewardship, and I look forward to being a part of Allogene as we work to expand access to CAR T for patients in need.”Before joining Allogene, Mr. Parker served as Chief Operating Officer, Chief Financial Officer and Executive Vice President of Tricida, Inc., which focused on the development of an investigational drug candidate for metabolic acidosis in patients with chronic kidney disease. Prior to that, Mr. Parker served as Chief Financial Officer of Anacor Pharmaceuticals, which was acquired by Pfizer in 2016 for approximately $5.2 billion, and served as a Managing Director at Goldman Sachs, where he led the West Coast Healthcare Investment Banking group. In addition, Mr. Parker currently serves as a member of the board of directors of Better Therapeutics and of Perrigo Company plc. Mr. Parker earned a B.A. with a double majo...